InDex Pharmaceuticals enrols first patient in the phase III study CONCLUDE with cobitolimod in ulcerative colitis
- Wednesday, November 24, 2021, 7:10
- PR Newswire
- Add a comment
STOCKHOLM, Nov. 24, 2021 /PRNewswire/ — InDex Pharmaceuticals Holding AB (publ) today announced that the first patient has been enrolled in the pivotal phase III study CONCLUDE. The study will evaluate the efficacy and safety of the first-in-class TLR9 agonist cobitolimod as a novel…
About the Author
admin has written 21717 stories on this site.